Application of a patient‐centered reverse translational systems‐based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors

Immunotherapy became a key pillar of cancer therapeutics with the approvals of ipilimumab, nivolumab, and pembrolizumab, which inhibit either cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) or programmed death‐1 (PD‐1) that are negative regulators of T‐cell activation. However, boosting T‐cell activation...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sarah, Lahu, Gezim, Vakilynejad, Majid, Soldatos, Theodoros G., Jackson, David B., Lesko, Lawrence J., Trame, Mirjam N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199880/
https://www.ncbi.nlm.nih.gov/pubmed/35191192
http://dx.doi.org/10.1111/cts.13254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199880/
https://www.ncbi.nlm.nih.gov/pubmed/35191192
http://dx.doi.org/10.1111/cts.13254

Ejemplares similares